NO20091265L - Pyrrolopyrazin som Syk-kinase inhibitor - Google Patents

Pyrrolopyrazin som Syk-kinase inhibitor

Info

Publication number: NO20091265L
Authority: NO; Norway
Prior art keywords: pyrrolopyrazine; kinase inhibitor; syk kinase; compound; prodrugs
Prior art date: 2006-09-11

Application number

NO20091265A

Other languages

English (en)

Norwegian (no)

Inventor

Timothy A Gillespy

Paul Eynott

Elizabeth M Allen

Kin T Yu

Asher Zilberstein

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-11

Filing date

2009-03-26

Publication date

2009-04-03

2009-03-26 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2009-04-03 Publication of NO20091265L publication Critical patent/NO20091265L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20091265A 2006-09-11 2009-03-26 Pyrrolopyrazin som Syk-kinase inhibitor NO20091265L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82516806P	2006-09-11	2006-09-11
PCT/US2007/078103 WO2008033798A2 (fr)	2006-09-11	2007-09-11	Inhibiteur de kinases

Publications (1)

Publication Number	Publication Date
NO20091265L true NO20091265L (no)	2009-04-03

Family

ID=39032357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091265A NO20091265L (no)	2006-09-11	2009-03-26	Pyrrolopyrazin som Syk-kinase inhibitor

Country Status (32)

Country	Link
US (2)	US8658649B2 (fr)
EP (1)	EP2094708B1 (fr)
JP (1)	JP5161237B2 (fr)
KR (1)	KR101443056B1 (fr)
CN (2)	CN103804383A (fr)
AR (1)	AR062745A1 (fr)
AU (1)	AU2007296592B8 (fr)
BR (1)	BRPI0716781A2 (fr)
CA (1)	CA2663175C (fr)
CL (1)	CL2007002617A1 (fr)
CO (1)	CO6160236A2 (fr)
CR (1)	CR10636A (fr)
DK (1)	DK2094708T3 (fr)
ES (1)	ES2437318T3 (fr)
GT (1)	GT200900055A (fr)
HN (1)	HN2009000455A (fr)
IL (1)	IL197381A (fr)
MA (1)	MA30781B1 (fr)
MX (1)	MX2009002616A (fr)
MY (1)	MY148107A (fr)
NI (1)	NI200900021A (fr)
NO (1)	NO20091265L (fr)
NZ (1)	NZ575496A (fr)
PE (1)	PE20081372A1 (fr)
PT (1)	PT2094708E (fr)
RU (1)	RU2440352C2 (fr)
TN (2)	TN2009000050A1 (fr)
TW (1)	TWI399379B (fr)
UA (1)	UA94622C2 (fr)
UY (1)	UY30584A1 (fr)
WO (1)	WO2008033798A2 (fr)
ZA (1)	ZA200901073B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2250172B1 (fr)	2008-02-25	2011-08-31	F. Hoffmann-La Roche AG	Inhibiteurs de kinase pyrrolopyrazine
PT2247592E (pt)	2008-02-25	2011-11-03	Hoffmann La Roche	Inibidores de pirrolpirazina-cinase
WO2009106441A1 (fr) *	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Inhibiteurs de la pyrrolopyrazine kinase
JP5485178B2 (ja)	2008-02-25	2014-05-07	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼ阻害剤
WO2009106444A1 (fr)	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Inhibiteurs de kinase pyrrolopyrazine
JP2011513488A (ja) *	2008-03-10	2011-04-28	サノフィ−アベンティス	眼関連障害の治療
FR2929851B1 (fr) *	2008-04-09	2012-11-30	Centre Nat Rech Scient	Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es)	2008-12-03	2010-07-27	Sanofi Aventis	Tratamiento para la glomerulonefritis
TW201033211A (en)	2008-12-04	2010-09-16	Sanofi Aventis	Crystalline forms
TW201034675A (en) *	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders
AR075869A1 (es) *	2009-03-19	2011-05-04	Sanofi Aventis	Sintesis de azaindoles
EP2516434B1 (fr)	2009-12-23	2015-05-27	Takeda Pharmaceutical Company Limited	Pyrrolidinones accolés en tant d'inhibiteurs de syk
US8518945B2 (en)	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8481541B2 (en)	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
WO2011144584A1 (fr)	2010-05-20	2011-11-24	F. Hoffmann-La Roche Ag	Dérivés de pyrrolopyrazine comme inhibiteurs de syk et jak
MX2012013378A (es) *	2010-05-20	2013-01-24	Hoffmann La Roche	Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk).
EP2441755A1 (fr)	2010-09-30	2012-04-18	Almirall, S.A.	Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2489663A1 (fr)	2011-02-16	2012-08-22	Almirall, S.A.	Composés en tant qu'inhibiteurs de la syk kinase
US9056873B2 (en)	2011-06-22	2015-06-16	Takeda Pharmaceutical Company Limited	Substituted 6-aza-isoindolin-1-one derivatives
BR112015002262A2 (pt) *	2012-08-21	2019-12-10	Hoffmann La Roche	compostos, métodos para os tratamentos de uma condição inflamatória, artrite reumatóide, asma e distúrbio imunológico; composição farmacêutica, utilização do composto e invenção
EP3027601B1 (fr)	2013-07-31	2017-10-25	Gilead Sciences, Inc.	Inhibiteurs syk
EP3942045A1 (fr)	2019-03-21	2022-01-26	Onxeo	Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
CN116969927B (zh) *	2023-06-07	2024-03-19	中南民族大学	一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1141949A (en)	1966-02-23	1969-02-05	Sterling Drug Inc	7-azaindole derivatives
US3992392A (en)	1973-04-27	1976-11-16	The Ohio State University Research Foundation	Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv)	1991-03-27	1991-03-27	Astra Ab	New active compounds
GB9226855D0 (en) *	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
US6075037A (en)	1994-06-09	2000-06-13	Smithkline Beecham Corporation	Endothelin receptor antagonists
FR2732969B1 (fr)	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT948495E (pt)	1996-11-19	2004-08-31	Amgen Inc	Agentes anti-inflamatorios de pirrolo fundido substituidos em arilo e heteroarilo
US6312835B1 (en)	1997-02-13	2001-11-06	Queen's University At Kingston	Luminescent compounds and methods of making and using same
SK125999A3 (en)	1997-03-19	2000-05-16	Knoll Ag	Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
WO1998047899A1 (fr)	1997-04-24	1998-10-29	Ortho-Mcneil Corporation, Inc.	Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
DE69830409T2 (de)	1997-08-05	2006-01-26	Pfizer Products Inc., Groton	4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten
KR100378937B1 (ko)	1997-10-20	2003-05-09	에프. 호프만-라 로슈 아게	바이사이클릭 키나아제 억제제
CA2322487C (fr)	1998-03-06	2010-07-20	Metabasis Therapeutics, Inc.	Nouveaux promedicaments pour composes contenant du phosphore
JP2002510685A (ja)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	性腺刺激ホルモン放出ホルモン拮抗薬
JP2002510630A (ja)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	性腺刺激ホルモン放出ホルモン拮抗薬
US6673797B1 (en)	1998-05-26	2004-01-06	Chugai Seiyaku Kabushiki Kaisha	Heterocyclic indole derivatives and mono- or diazaindole derivatives
AU752474B2 (en)	1998-09-18	2002-09-19	Abbott Gmbh & Co. Kg	4-aminopyrrolopyrimidines as kinase inhibitors
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB9930698D0 (en) *	1999-12-24	2000-02-16	Rhone Poulenc Rorer Ltd	Chemical compounds
IL150388A0 (en) *	1999-12-24	2002-12-01	Aventis Pharma Ltd	Azaindoles
US6770666B2 (en)	1999-12-27	2004-08-03	Japan Tobacco Inc.	Fused-ring compounds and use thereof as drugs
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de)	2000-02-25	2001-08-30	Basf Ag	Verfahren zur Herstellung substituierter Indole
EP1265897A1 (fr)	2000-03-20	2002-12-18	Axys Pharmaceuticals, Inc.	Inhibiteurs de la protease exempte d'amidine
JP2001302667A (ja) *	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
AU2001261189A1 (en)	2000-05-03	2001-11-12	Tularik, Inc.	Pyrazole antimicrobial agents
BR0111544A (pt)	2000-06-14	2003-07-01	Warner Lambert Co	Heterociclos bicìclicos 6,5-fundidos
EP1324985A4 (fr)	2000-10-02	2004-10-06	Merck & Co Inc	Inhibiteurs de la prenyl-proteine transferase
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (fr)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthese de composes heterocycliques faisant appel a une technologie micro-onde
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
MXPA04003954A (es)	2001-10-26	2004-11-29	Aventis Pharma Inc	Bencimidazoles.
US20040082365A1 (en) *	2002-07-18	2004-04-29	Celerica Ltd	Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (fr)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines utilisées comme inhibiteurs de kinases
WO2005014543A1 (fr)	2003-08-06	2005-02-17	Japan Tobacco Inc.	Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc
SG156685A1 (en) *	2004-07-27	2009-11-26	Sgx Pharmaceuticals Inc	Fused ring heterocycle kinase modulators
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1809279B1 (fr)	2004-11-08	2013-05-29	Baxter International Inc.	Compositions particulaires d'inhibiteurs de la tubuline
CA2587926A1 (fr) *	2004-11-22	2006-06-01	Vertex Pharmaceuticals Incorporated	Inhibiteurs bicycliques de rho kinase
US20110112101A1 (en)	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders

2007
- 2007-09-10 CL CL200702617A patent/CL2007002617A1/es unknown
- 2007-09-11 KR KR1020097005040A patent/KR101443056B1/ko not_active Expired - Fee Related
- 2007-09-11 DK DK07842207.8T patent/DK2094708T3/da active
- 2007-09-11 JP JP2009538434A patent/JP5161237B2/ja not_active Expired - Fee Related
- 2007-09-11 BR BRPI0716781-4A2A patent/BRPI0716781A2/pt not_active IP Right Cessation
- 2007-09-11 WO PCT/US2007/078103 patent/WO2008033798A2/fr not_active Ceased
- 2007-09-11 EP EP07842207.8A patent/EP2094708B1/fr active Active
- 2007-09-11 UY UY30584A patent/UY30584A1/es not_active Application Discontinuation
- 2007-09-11 MX MX2009002616A patent/MX2009002616A/es active IP Right Grant
- 2007-09-11 CA CA2663175A patent/CA2663175C/fr not_active Expired - Fee Related
- 2007-09-11 RU RU2009113615/04A patent/RU2440352C2/ru not_active IP Right Cessation
- 2007-09-11 AU AU2007296592A patent/AU2007296592B8/en not_active Ceased
- 2007-09-11 CN CN201310652393.XA patent/CN103804383A/zh active Pending
- 2007-09-11 MY MYPI20090720A patent/MY148107A/en unknown
- 2007-09-11 ES ES07842207.8T patent/ES2437318T3/es active Active
- 2007-09-11 CN CNA2007800336608A patent/CN101511838A/zh active Pending
- 2007-09-11 NZ NZ575496A patent/NZ575496A/en not_active IP Right Cessation
- 2007-09-11 PT PT78422078T patent/PT2094708E/pt unknown
- 2007-09-11 AR ARP070104013A patent/AR062745A1/es not_active Application Discontinuation
- 2007-09-11 PE PE2007001220A patent/PE20081372A1/es not_active Application Discontinuation
- 2007-09-11 TW TW096133786A patent/TWI399379B/zh not_active IP Right Cessation
- 2007-11-09 UA UAA200903417A patent/UA94622C2/ru unknown
2009
- 2009-02-16 ZA ZA2009/01073A patent/ZA200901073B/en unknown
- 2009-02-17 TN TN2009000050A patent/TN2009000050A1/fr unknown
- 2009-02-17 TN TN2009000049A patent/TN2009000049A1/fr unknown
- 2009-02-17 NI NI200900021A patent/NI200900021A/es unknown
- 2009-02-25 CR CR10636A patent/CR10636A/es not_active Application Discontinuation
- 2009-03-03 IL IL197381A patent/IL197381A/en not_active IP Right Cessation
- 2009-03-10 GT GT200900055A patent/GT200900055A/es unknown
- 2009-03-10 US US12/401,254 patent/US8658649B2/en not_active Expired - Fee Related
- 2009-03-10 HN HN2009000455A patent/HN2009000455A/es unknown
- 2009-03-11 CO CO09025278A patent/CO6160236A2/es unknown
- 2009-03-26 NO NO20091265A patent/NO20091265L/no not_active Application Discontinuation
- 2009-04-06 MA MA31765A patent/MA30781B1/fr unknown
2014
- 2014-01-28 US US14/166,396 patent/US20140142110A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2437318T3 (es)	2014-01-10
WO2008033798A2 (fr)	2008-03-20
IL197381A0 (en)	2009-12-24
KR101443056B1 (ko)	2014-09-22
CR10636A (es)	2009-03-20
PE20081372A1 (es)	2008-11-27
US20100035884A1 (en)	2010-02-11
KR20090063214A (ko)	2009-06-17
EP2094708B1 (fr)	2013-10-23
TN2009000050A1 (en)	2010-08-19
HN2009000455A (es)	2012-02-13
ZA200901073B (en)	2009-12-30
RU2009113615A (ru)	2010-10-20
DK2094708T3 (da)	2014-01-27
AU2007296592A1 (en)	2008-03-20
TW200829590A (en)	2008-07-16
NI200900021A (es)	2010-01-29
GT200900055A (es)	2010-07-28
CO6160236A2 (es)	2010-05-20
EP2094708A2 (fr)	2009-09-02
JP2010502767A (ja)	2010-01-28
AR062745A1 (es)	2008-12-03
MX2009002616A (es)	2009-03-24
US8658649B2 (en)	2014-02-25
US20140142110A1 (en)	2014-05-22
JP5161237B2 (ja)	2013-03-13
AU2007296592B8 (en)	2012-01-12
UA94622C2 (en)	2011-05-25
NZ575496A (en)	2011-09-30
IL197381A (en)	2013-11-28
CL2007002617A1 (es)	2008-05-16
CA2663175C (fr)	2012-03-13
MA30781B1 (fr)	2009-10-01
AU2007296592B2 (en)	2011-12-15
MY148107A (en)	2013-02-28
CA2663175A1 (fr)	2008-03-20
WO2008033798A3 (fr)	2008-05-15
PT2094708E (pt)	2014-01-07
RU2440352C2 (ru)	2012-01-20
BRPI0716781A2 (pt)	2014-11-18
UY30584A1 (es)	2008-05-02
CN103804383A (zh)	2014-05-21
TWI399379B (zh)	2013-06-21
CN101511838A (zh)	2009-08-19
TN2009000049A1 (en)	2010-08-19

Publication	Publication Date	Title
NO20091265L (no)	2009-04-03	Pyrrolopyrazin som Syk-kinase inhibitor
WO2006123113A3 (fr)	2007-01-04	Composes chimiques
NO20083717L (no)	2008-10-06	Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
MX2009010595A (es)	2009-10-22	Derivados de pirrolopirimidina.
NO20073791L (no)	2007-08-30	Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
MX2009011579A (es)	2009-11-11	Pirimidinonas como moduladores de caseina cinasa ii (ck2).
WO2008022286A3 (fr)	2008-04-17	petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
SE0400284D0 (sv)	2004-02-10	Novel compounds
WO2009155121A3 (fr)	2010-02-18	Inhibiteurs de la pi3 kinase
NO20090025L (no)	2009-02-02	Pyrrolotriazinkinaseinhibitorer
NO20083267L (no)	2008-09-04	Azaindole inhibitorer av aurora kinaser
NO20076066L (no)	2008-01-07	Oksadiazolderivater som DGAT-inhibitorer
WO2005110410A3 (fr)	2007-03-29	Inhibiteurs de kinases en tant qu'agents therapeutiques
MX2010004263A (es)	2010-05-03	Inhibidores de quinasa c-fms.
NO20081454L (no)	2008-04-22	Met-kinaseinhibitorer
WO2009016460A8 (fr)	2009-10-15	Composés pyrazoles
UA94129C2 (ru)	2011-04-11	Соединения для ингибирования митоза
SMT201300109B (it)	2013-11-08	Imidazopiridazincarbonitrili utili come inibitori di chinasi
WO2010014930A3 (fr)	2010-07-29	Agents thérapeutiques
NO20081893L (no)	2008-05-20	4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
TNSN08191A1 (en)	2009-10-30	Kinase inhibitors
MX2009007302A (es)	2009-07-15	Derivados de purina.
PT2421879E (pt)	2013-12-09	Novos 7-deazapurina nucleósidos para utilizações terapêuticas
PL1899329T3 (pl)	2012-03-30	Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych

Legal Events

Date	Code	Title	Description
2015-04-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application